138 related articles for article (PubMed ID: 18754023)
1. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials.
Lucas CM; Wang L; Austin GM; Knight K; Watmough SJ; Shwe KH; Dasgupta R; Butt NM; Galvani D; Hoyle CF; Seale JR; Clark RE
Leukemia; 2008 Oct; 22(10):1963-6. PubMed ID: 18754023
[No Abstract] [Full Text] [Related]
2. [Treatment of chronic myeloid leukemia with imatinib].
Ohnishi K
Gan To Kagaku Ryoho; 2011 May; 38(5):746-8. PubMed ID: 21702117
[No Abstract] [Full Text] [Related]
3. Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib.
Wang L; Butt NM; Atherton MG; Clark RE
Leukemia; 2004 May; 18(5):1025-7. PubMed ID: 15014531
[No Abstract] [Full Text] [Related]
4. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
Smith BD
J Natl Cancer Inst; 2011 Apr; 103(7):527-9. PubMed ID: 21422404
[No Abstract] [Full Text] [Related]
5. Imatinib in chronic myeloid leukemia.
Krause SW; Holler E
N Engl J Med; 2007 Apr; 356(17):1780; author reply 1780. PubMed ID: 17460235
[No Abstract] [Full Text] [Related]
6. Clinical characteristics and hematologic responses to Imatinib in patients with chronic phase myeloid leukemia (CML) at Cipto Mangunkusumo Hospital.
Reksodiputro AH; Syafei S; Prayogo N; Karsono B; Rinaldi I; Rajabto W; Mulansari NA
Acta Med Indones; 2010 Jan; 42(1):2-5. PubMed ID: 20305324
[TBL] [Abstract][Full Text] [Related]
7. How long will chronic myeloid leukemia patients treated with imatinib mesylate live?
Hasford J; Pfirrmann M; Hochhaus A
Leukemia; 2005 Apr; 19(4):497-9. PubMed ID: 15861176
[No Abstract] [Full Text] [Related]
8. Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a 'grey zone' at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention.
Breccia M; Orlandi SM; Latagliata R; Grammatico S; Diverio D; Mancini M; Loglisci G; Salaroli A; Federico V; Santopietro M; Alimena G
Br J Haematol; 2011 Jan; 152(1):119-21. PubMed ID: 21029071
[No Abstract] [Full Text] [Related]
9. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
10. Atypical chronic myeloid leukaemia with CD117-positive blast cells treated with imatinib: A report of two cases.
Breccia M; Russo E; De Propris MS; Frustaci A; Alimena G
Acta Haematol; 2006; 116(3):211-2. PubMed ID: 17016042
[No Abstract] [Full Text] [Related]
11. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
12. Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia.
Mariani S; Tornaghi L; Sassone M; Basciani S; Buzzetti R; Gambacorti-Passerini C; Spera G; Gnessi L
Leuk Res; 2010 Jan; 34(1):e5-7. PubMed ID: 19717189
[No Abstract] [Full Text] [Related]
13. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
Jabbour E; Kantarjian H; Jones D; Talpaz M; Bekele N; O'Brien S; Zhou X; Luthra R; Garcia-Manero G; Giles F; Rios MB; Verstovsek S; Cortes J
Leukemia; 2006 Oct; 20(10):1767-73. PubMed ID: 16855631
[TBL] [Abstract][Full Text] [Related]
14. STI-571 (Gleevec) in the treatment of chronic myeloid leukaemia.
Kumar L; Kumari M; Menon H
Natl Med J India; 2002; 15(5):298. PubMed ID: 12502149
[No Abstract] [Full Text] [Related]
15. Antituberculosis therapy and imatinib for chronic myeloid leukemia.
Sorà F; De Matteis S; Di Mario A; Maiuro G; Laurenti L; Chiusolo P; Ardito F; Leone G; Sica S
Clin Infect Dis; 2006 Nov; 43(9):1224. PubMed ID: 17029152
[No Abstract] [Full Text] [Related]
16. Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment.
Breccia M; Muscaritoli M; Cannella L; Loglisci G; Santopietro M; Alimena G
Leuk Res; 2010 May; 34(5):e122-4. PubMed ID: 20018374
[No Abstract] [Full Text] [Related]
17. Revised advice on use of imatinib for chronic myeloid leukaemia.
Campbell K
Nurs Times; 2003 Oct 14-20; 99(41):20-1. PubMed ID: 14603651
[TBL] [Abstract][Full Text] [Related]
18. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
[No Abstract] [Full Text] [Related]
19. Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment.
Kawakami Y; Nakamura K; Nishibu A; Yanagihori H; Kimura H; Yamamoto T
Acta Derm Venereol; 2008; 88(2):185-6. PubMed ID: 18311459
[No Abstract] [Full Text] [Related]
20. Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
Roche-Lestienne C; Darré S; Laï JL; Facon T; Guilhot J; Preudhomme C
Haematologica; 2005 Jan; 90(1):131-3. PubMed ID: 15642682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
